Subscribe to our newsletter

Investor Resources

Who We Are

Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using our drug discovery platform with a data-driven approach. Liminal BioSciences has its registered office in Bellevlle, Ontario and talent hubs in Laval, Quebec, Canada, and Cambridge, UK.

Our common shares are listed for trading on the Nasdaq Market (LMNL).

Stock Quote
NASDAQLMNL
OUR DEVELOPMENT PROGRAMS

GPR84 Antagonist

The GPR84 receptor is primarily expressed in immune cells in addition to multiple organ systems. It plays a key role in the linkage and regulation of the inflammatory and metabolic response, and promotes fibrosis. Learn more.

OXER1 Antagonist 

OXER1 is a GPCR receptor which is mainly expressed ininflammatory cells. OXER1 is highly selective for 5 oxo ETE, one of the most powerful chemo attractants and activators of eosinophils. Learn more.

Recent News
Sep 19, 2023
LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List)...

Sep 15, 2023
LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under...

Sep 12, 2023
LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the...

More News

Latest Events
Q4 and Year End 2022 Financial Results Conference Call
Thursday, March 16, 2023
8:30am - 9:30am EDT

Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday March 16, 2023. To join the conference call without operator assistance, you may register...

Q3 2022 Results Conference Call
Thursday, November 10, 2022
8:30am - 9:30am EST

Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the conference call are 888-205-6786 and...

H.C. Wainwright 24th Annual Global Investment Conference - September 12-14, 2022
Wednesday, September 14, 2022
9:30am EDT
Investor Resources

Find out more on how Liminal BioSciences (NASDAQ: LMNL) is developing a pipeline of novel small molecule therapeutics.